New Enterprise Associates 17, L.P. → Monte Rosa Therapeutics, Inc. GLUE

Stake: — Shares: 6,692,298 Class: Common Stock, par value $0.0001 per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-07-31

DTC 10.59

16,458,543 shares short · -4.3% vs prior

Institutional Consensus · 2026-06-30

Held by elite portfolio managers

1 holder · $7K

Duquesne Family Office

Post-Filing Returns · since 2026-07-01 on GLUE

+1 day

0.0%

+5 days

0.0%

+30 days

—

+60 days

—

+90 days

—

+180 days

—

Anchor price 24.40 on closest trading day on/after 2026-07-01. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other 13D/G Filings on Monte Rosa Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-01-09	SCHEDULE	Versant Venture Capital VI, L.P.	3.40%	2,236,708	view →
2025-11-12	SCHEDULE	Versant Venture Capital VI, L.P.	5.10%	3,334,669	view →

Other Filings by New Enterprise Associates 17, L.P.

Filed	Form	Issuer	Stake	Shares
2025-10-06	SCHEDULE	NeueHealth, Inc.	—	—	view →
2024-10-21	SC	Inventiva S.A. IVEVF	—	—	view →
2024-05-03	SC	Inventiva S.A. IVEVF	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →